The adult sermorelin literature is mostly physiology probes. The two studies most often cited for aging tested a norleucine analog, not sermorelin, and the best-known adult framing is an editorial with no abstract.
The ghrelin receptor sits in the gut as well as the pituitary. Rodent studies of ipamorelin and bowel recovery led to the one human trial of the compound — which did not beat placebo.
Rat studies of ipamorelin measured bone length, bone mineral content and muscle tension. The results are more qualified than most summaries admit — including a finding that bone density did not change.
Two FDA applications for sermorelin acetate exist, first approved December 28 1990 and September 26 1997, both discontinued with an FDA determination that it was not for safety or effectiveness reasons.
CJC-1295 and ipamorelin are sold as a pair. PubMed returns ten records mentioning both, all reviews, and no human study of the combination. What the closest related evidence actually shows.
Tesamorelin is a modified GHRH analog studied almost entirely in HIV-associated lipodystrophy, where a licensed product has a Phase 3 record. What the research covers, where it stops, and what the mechanism annotation says.
Tesamorelin and sermorelin are both GHRH analogs, but one is the full 44-residue hormone with a stabilizing cap and the other is a 29-residue fragment. Verified identity, half-life, regulatory and trial records, side by side.
Tesamorelin is a 44-residue GHRH analog with a trans-3-hexenoyl group on Tyr1 and a C-terminal amide. One molecular weight (5136) is verified; the others in circulation are not.
What the tesamorelin safety record contains: the glucose composite, class-typical adverse events, a FAERS carpal-tunnel signal, sponsor animal toxicology, and the evidence that does not exist at all.
Outside HIV-associated lipodystrophy, tesamorelin research collapses to single small trials, re-analyses and nulls: one obesity cohort published twice, one liver trial, a split cognition record, zero muscle or sport studies.